Lexeo's PKP2 cardiomyopathy gene therapy adds RMAT status

Reports

3

Domains carrying it

3

First reported

6 August 2026

Latest report

11 August 2026

◆ Sectors

◆ Where

United States

◆ Timeline

1. 6 August 2026Lexeo Therapeutics' LX2020 Receives FDA RMAT Designation for PKP2 Cardiomyopathyclinicaltrialvanguard.com
2. 11 August 2026Lexeo wins FDA RMAT status for LX2020pharmatimes.com

◆ Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

• Capricor soars on potential FDA review extension, filing amendments9 reports · 6 domains · 25 August 2026
• IPS HEART's iPSC-Derived Cell Therapy, ISX9-CPC, Secures 8th FDA Regulatory Milestone2 reports · 2 domains · 17 August 2026
• Safety concerns spur FDA to again halt testing of Regenxbio gene therapy3 reports · 3 domains · 31 August 2026
• Regeneron Pharmaceuticals Announces FDA Approval of Pasatru for Adults With ...11 reports · 8 domains · 31 August 2026
• FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults10 reports · 10 domains · 2 September 2026
• FDA Allows First Gene Therapy Clinical Trial for Ultra-Rare Pediatric Neurodegenerative Disease2 reports · 2 domains · 4 September 2026

◆ Share

◆ Evidence

3 reports · 3 domains

• Lexeo wins FDA RMAT status for LX2020pharmatimes.com · 11 August 2026
• Lexeo's PKP2 cardiomyopathy gene therapy adds RMAT statusallsci.com · 6 August 2026
• Lexeo Therapeutics' LX2020 Receives FDA RMAT Designation for PKP2 Cardiomyopathyclinicaltrialvanguard.com · 6 August 2026